Teresa Cesena

The medical writing and transparency teams have grown significantly under her leadership, and one of her key responsibilities has been to ensure that onboarding, training, and mentoring continue to maintain high levels of quality. Teresa oversees initiatives that enable the team to stay ahead of industry trends and regulations and is responsible for overseeing teams who can execute deliverables in a variety of models, including in FSP partnerships. In addition, she manages teams with expertise in related technologies and tech-enabled solutions, like Automatiqc® quality tool.

She holds a Ph.D. in Cellular and Molecular Biology from the University of Michigan and is an instructor for MMS Academy.

Suggested For You

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months